In addition, CSF CXCL13 levels were found incremented in MS patients (Khademi et al., 2011), in which they are correlated with a high number of CSF CD5+ B cells and with intrathecal IgM production (Krumbholz et al., 2006; Villar et al., 2010; Ferraro et al., 2015). This evidence concerns the gene CSF2 and myeloid sarcoma.